Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer
Abstract
High phytoestrogen intake among Asian women has been thought to explain the low risk of bone fractures in these populations. In a randomized placebo-controlled trial we studied the effects of isoflavonoids on urinary output of the N-terminal cross-linked telopeptide of type I collagen, pyridinoline (Pyr), and deoxypyridinoline (Dpyr) (bone resorption markers) and serum levels of bone-specific alkaline phosphatase and N-terminal and C-terminal procollagen type I (bone formation markers). Fifty-five postmenopausal women with a history of breast cancer used phytoestrogens (114 mg of isoflavonoids) or placebo tablets daily for 3 months; the treatment regimens were then crossed over after a 2-month washout period. The markers were measured before and on the last day of each treatment period. Bone resorption was reduced during phytoestrogen use, as reflected in falls in the urinary output of Pyr (9%; P = 0.001) and Dpyr (5%; P = 0.008). Compared with the placebo group, the fall in Dpyr was significant (P = 0.022) and the falls in Pyr (P = 0.084) and N-terminal cross-linked telopeptide of type I collagen (P = 0.082) showed a trend toward significance. Bone formation markers were not affected by this regimen. Thus, isoflavonoid-induced inhibition of bone resorption may contribute to the low risk of osteoporosis in Asian women.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among all studies, there was report of only one case of breast cancer recurrence that occurred in a soy-allocated subject; and two new cases of breast cancer and one case of endometrial cancer among soy allocated subjects compared to five in control subjects.
“Amongst all the studies, there was report of only one case of breast cancer recurrence that occurred in a soy-allocated subject [142]; and two new cases of breast cancer and one case of endometrial cancer among soy allocated subjects compared to five in the control subjects [132,145,147,160].”
From Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review (2013) · cites this paper as [142]
The most common adverse event associated with soy consumption was mild to moderate gastrointestinal discomfort, usually occurring with comparable frequency in soy and placebo groups.
“The most common adverse event associated with soy consumption was mild to moderate gastrointestinal discomfort, but this usually occurred with comparable frequency in both the soy and the placebo groups [128,130,131,136,142,147,150]; only in one study was there considerable difference in the frequency of GI upset, 47% in the soy group compared to 22% in the control group [130].”
From Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review (2013) · cites this paper as [142]
Cited by
Sorted by citations
Sacks, F. M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P., & Winston, M. (2006) · Circulation · doi:10.1161/circulationaha.106.171052 · Cited by 656 · see citing works
Soy, Red Clover, and Isoflavones and Breast Cancer: A Systematic Review
Fritz, H., Seely, D., Flower, G., Skidmore, B., Fernandes, R., Vadeboncoeur, S., Kennedy, D., Cooley, K., Wong, R., Sagar, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081968 · Cited by 188 · see citing works
Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions
Chen, L.-R., Ko, N.-Y., & Chen, K.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092213 · Cited by 116 · see citing works
Kang, J. S., Yoon, Y. D., Han, M. H., Han, S.-B., Lee, K., Kang, M. R., Moon, E.-Y., Jeon, Y. J., Park, S.-K., & Kim, H. M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.009 · Cited by 43 · see citing works
- Authors
- Nikander, E., Metsä-Heikkilä, M., Ylikorkala, O., & Tiitinen, A.
- Affiliations
- Helsinki University Hospital (FI)
- University of Helsinki (FI)
- Corresponding author
- Nikander, Eini
- ORCID
- Tiitinen, Aila
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-03
- Volume
- 89
- Issue
- 3
- Pages
- 1207-1212
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2127119599
- Cited by
- 56
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 3
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Phytoestrogen effects and research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- phytoestrogens, isoflavonoids, bone turnover, bone resorption, bone formation, postmenopausal women, breast cancer survivors, osteoporosis, pyridinoline, deoxypyridinoline, bone-specific alkaline phosphatase, Asian women, fracture risk
- MeSH terms
- Adult, Aged, Breast Neoplasms, Female, Humans, Isoflavones, Middle Aged, Risk Factors, Osteoporosis, Postmenopausal, Bone Remodeling, Postmenopause, Cross-Over Studies, Hot Flashes, Plant Preparations, Phytoestrogens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review